Cytogenetics News and Research

RSS

Cytogenetics is a field of study that deals with chromosomes and related abnormalities. Chromosome analysis is also known as karyotyping and involves the pairing of homologous chromosomes.

Novel prognostic model for patients with treatment-related MDS

A large-scale analysis of patients whose myelodysplastic syndrome is related to earlier cancer treatment overturns the notion that all of them have a poor prognosis, researchers from The University of Texas MD Anderson Cancer Center report at the 53rd Annual Meeting of the American Society of Hematology.

15 Dec 2011

Onyx announces data from three carfilzomib studies on RRMM

Onyx Pharmaceuticals, Inc. today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

12 Dec 2011

Celgene announces results from azacitidine Phase 1 study on AML

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced results from a multi-center Phase I study that explored multiple dosing schedules of oral azacitidine in 23 patients with acute myeloid leukemia (AML), myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML) who were not candidates for other therapies or who had failed previous regimens.

12 Dec 2011

Affymetrix signs definitive agreement to acquire eBioscience

Affymetrix, Inc., today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.

30 Nov 2011

Transgenomic third quarter total revenue increases 87% to $8.3 million

Transgenomic, Inc. today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.

10 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

Transgenomic and A. Menarini Diagnostics enter distribution agreement for mutation detection systems

Transgenomic, Inc. and A. Menarini Diagnostics today announced an exclusive distribution agreement for Transgenomic's SURVEYOR Scan and WAVE MCE (Micro-Capillary Electrophoresis) Mutation Detection system to its network of over 2,000 pathologists throughout Europe.

7 Nov 2011

NeoGenomics third quarter revenue increases 30% to $11.3 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the third quarter 2011.

19 Oct 2011

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

YM BioSciences Inc. today announced that it has enrolled the first patients in its multi-center Phase II trial of CYT387 administered twice-daily (BID) for the treatment of myelofibrosis.

28 Sep 2011

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

14 Jul 2011

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

13 Jul 2011

Cumulus cells can provide information about genetic and chromosomal status of eggs

At present, when a woman undergoes preimplantation genetic screening (PGS) in a fertility clinic, doctors are trying to select an egg or an embryo that is healthy and doesn't have a chromosome abnormality such as an extra copy of chromosome 21, which causes Down's syndrome. In order to establish this, they either have to biopsy a part of the egg called the polar body or remove a cell from the embryo for screening. Both procedures are expensive, invasive and can damage the egg or embryo.

6 Jul 2011

Start of clinical validation study of Down’s syndrome diagnostic test

In conjunction with several Central European prenatal centers, scientists at GATC Biotech AG and LifeCodexx AG have begun the clinical validation study of a non-invasive, prenatal diagnostic test based on next generation sequencing.

28 Jun 2011

Data from microarrays co-developed by OGT to be presented at ECC 2011

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced details of its upcoming workshop at the European Cytogenetics Conference 2011, held in Porto, Portugal (2–5 July).

From Oxford Gene Technology 28 Jun 2011

AIS introduces Spectral karyotyping

AIS introduces Spectral karyotyping (SKY®) equipment, designed and manufactured by ASI, a leading developer of comprehensive solutions for pathology and cytogenetics. Spectral karyotyping (SKY®) is ASI’s novel addition to the cytogenetic tool kit. It is based on a unique electro-optical hardware that enables measuring the spectral image of a metaphase, previously stained, such that each chromosome class has a different color (created typically from different combinations of 5 or more basic dyes).

23 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Affymetrix reports total revenue of $73.7 million for first quarter 2011

Affymetrix, Inc., today reported its operating results for the first quarter of 2011. Total revenue for the quarter was $73.7 million, as compared to total revenue of $80.2 million in the first quarter of 2010.

28 Apr 2011

CSI's cancer cytogenetic testing receives COG approval

CSI Laboratories, a private national cancer diagnostics laboratory, has received approval from the Children's Oncology Group to begin analyzing pediatric cytogenetic cases. The Children's Oncology Group is the world's largest children's cancer research organization and includes more than 210 member hospitals with over 6,500 medical professionals.

26 Apr 2011

March of Dimes honors Whitehead Institute Director for Developmental Biology work

Whitehead Institute Director David Page has been named a recipient of the 2011 March of Dimes Prize in Developmental Biology. The prize honors Page's groundbreaking body of research on the human Y chromosome.

22 Apr 2011

NCI, ASH, AMEH join to improve care for patients with AML

A workshop being held today will serve as the launch of a unique project that unites the American Society of Hematology, the Agrupaci-n Mexicana para el Estudio de la Hematolog-a, and the National Cancer Institute in pursuit of a common goal: improving the care of patients with acute myeloid leukemia.

11 Apr 2011